The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Leads development of an integrated evidence strategy across Clinical Development, Medical Affairs, HEOR, Real-World Evidence, Market Access, and Commercial to address the evolving needs of patients, healthcare professionals, payers, health systems, and other stakeholders.